CLDX
Price
$18.33
Change
-$1.19 (-6.10%)
Updated
May 9 closing price
Capitalization
1.22B
89 days until earnings call
GERN
Price
$1.18
Change
-$0.08 (-6.35%)
Updated
May 9 closing price
Capitalization
751.56M
89 days until earnings call
Ad is loading...

CLDX vs GERN

Header iconCLDX vs GERN Comparison
Open Charts CLDX vs GERNBanner chart's image
Celldex Therapeutics
Price$18.33
Change-$1.19 (-6.10%)
Volume$1M
Capitalization1.22B
Geron
Price$1.18
Change-$0.08 (-6.35%)
Volume$15.89M
Capitalization751.56M
CLDX vs GERN Comparison Chart
Loading...
CLDX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
GERN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CLDX vs. GERN commentary
May 11, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CLDX is a Hold and GERN is a Hold.

Ad is loading...
COMPARISON
Comparison
May 11, 2025
Stock price -- (CLDX: $18.33 vs. GERN: $1.18)
Brand notoriety: CLDX and GERN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CLDX: 125% vs. GERN: 117%
Market capitalization -- CLDX: $1.22B vs. GERN: $751.56M
CLDX [@Biotechnology] is valued at $1.22B. GERN’s [@Biotechnology] market capitalization is $751.56M. The market cap for tickers in the [@Biotechnology] industry ranges from $296.96B to $0. The average market capitalization across the [@Biotechnology] industry is $2.18B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CLDX’s FA Score shows that 0 FA rating(s) are green whileGERN’s FA Score has 0 green FA rating(s).

  • CLDX’s FA Score: 0 green, 5 red.
  • GERN’s FA Score: 0 green, 5 red.
According to our system of comparison, CLDX is a better buy in the long-term than GERN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CLDX’s TA Score shows that 5 TA indicator(s) are bullish while GERN’s TA Score has 5 bullish TA indicator(s).

  • CLDX’s TA Score: 5 bullish, 5 bearish.
  • GERN’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, GERN is a better buy in the short-term than CLDX.

Price Growth

CLDX (@Biotechnology) experienced а -11.28% price change this week, while GERN (@Biotechnology) price change was -14.49% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -6.24%. For the same industry, the average monthly price growth was +9.39%, and the average quarterly price growth was -13.47%.

Reported Earning Dates

CLDX is expected to report earnings on Aug 07, 2025.

GERN is expected to report earnings on Aug 07, 2025.

Industries' Descriptions

@Biotechnology (-6.24% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CLDX($1.22B) has a higher market cap than GERN($752M). CLDX YTD gains are higher at: -27.463 vs. GERN (-66.667). GERN has higher annual earnings (EBITDA): -154.85M vs. CLDX (-191.9M). CLDX has more cash in the bank: 725M vs. GERN (407M). CLDX has less debt than GERN: CLDX (3.81M) vs GERN (122M). GERN has higher revenues than CLDX: GERN (77M) vs CLDX (7.02M).
CLDXGERNCLDX / GERN
Capitalization1.22B752M162%
EBITDA-191.9M-154.85M124%
Gain YTD-27.463-66.66741%
P/E RatioN/AN/A-
Revenue7.02M77M9%
Total Cash725M407M178%
Total Debt3.81M122M3%
FUNDAMENTALS RATINGS
CLDX vs GERN: Fundamental Ratings
CLDX
GERN
OUTLOOK RATING
1..100
624
VALUATION
overvalued / fair valued / undervalued
1..100
58
Fair valued
92
Overvalued
PROFIT vs RISK RATING
1..100
66100
SMR RATING
1..100
9194
PRICE GROWTH RATING
1..100
5893
P/E GROWTH RATING
1..100
10069
SEASONALITY SCORE
1..100
8585

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CLDX's Valuation (58) in the Biotechnology industry is somewhat better than the same rating for GERN (92). This means that CLDX’s stock grew somewhat faster than GERN’s over the last 12 months.

CLDX's Profit vs Risk Rating (66) in the Biotechnology industry is somewhat better than the same rating for GERN (100). This means that CLDX’s stock grew somewhat faster than GERN’s over the last 12 months.

CLDX's SMR Rating (91) in the Biotechnology industry is in the same range as GERN (94). This means that CLDX’s stock grew similarly to GERN’s over the last 12 months.

CLDX's Price Growth Rating (58) in the Biotechnology industry is somewhat better than the same rating for GERN (93). This means that CLDX’s stock grew somewhat faster than GERN’s over the last 12 months.

GERN's P/E Growth Rating (69) in the Biotechnology industry is in the same range as CLDX (100). This means that GERN’s stock grew similarly to CLDX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CLDXGERN
RSI
ODDS (%)
Bearish Trend 2 days ago
86%
Bullish Trend 2 days ago
78%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 2 days ago
71%
Momentum
ODDS (%)
Bearish Trend 2 days ago
79%
Bearish Trend 2 days ago
80%
MACD
ODDS (%)
Bearish Trend 2 days ago
80%
Bullish Trend 2 days ago
76%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
84%
Bearish Trend 2 days ago
82%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
80%
Bearish Trend 2 days ago
81%
Advances
ODDS (%)
Bullish Trend 3 days ago
82%
Bullish Trend 10 days ago
75%
Declines
ODDS (%)
Bearish Trend 5 days ago
81%
Bearish Trend 2 days ago
76%
BollingerBands
ODDS (%)
Bullish Trend 4 days ago
77%
Bullish Trend 2 days ago
84%
Aroon
ODDS (%)
Bullish Trend 2 days ago
76%
Bearish Trend 2 days ago
77%
View a ticker or compare two or three
Ad is loading...
CLDX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
GERN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
HRLCX8.60N/A
N/A
Hartford Real Asset C
PABVX15.04N/A
N/A
Principal MidCap Value I R5
VEVCX42.60N/A
N/A
Victory Sycamore Established Value C
VPRDX16.17N/A
N/A
VY® Morgan Stanley Global Franchise R6
GHTRX14.08N/A
N/A
Goldman Sachs International T/M Eq R6

CLDX and

Correlation & Price change

A.I.dvisor indicates that over the last year, CLDX has been loosely correlated with BEAM. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if CLDX jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CLDX
1D Price
Change %
CLDX100%
-6.10%
BEAM - CLDX
53%
Loosely correlated
+0.93%
KYMR - CLDX
49%
Loosely correlated
-2.27%
NTLA - CLDX
49%
Loosely correlated
-1.93%
RVMD - CLDX
48%
Loosely correlated
-3.56%
DNLI - CLDX
48%
Loosely correlated
-0.42%
More

GERN and

Correlation & Price change

A.I.dvisor indicates that over the last year, GERN has been loosely correlated with SER. These tickers have moved in lockstep 66% of the time. This A.I.-generated data suggests there is some statistical probability that if GERN jumps, then SER could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GERN
1D Price
Change %
GERN100%
-6.35%
SER - GERN
66%
Loosely correlated
-2.01%
LIANY - GERN
53%
Loosely correlated
N/A
VCYT - GERN
44%
Loosely correlated
-4.81%
MIRM - GERN
39%
Loosely correlated
-2.14%
DAWN - GERN
38%
Loosely correlated
-4.59%
More